We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
-4%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.26B
AUM Growth
-$362M
Cap. Flow
-$5M
Cap. Flow %
-0.12%
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17

Top Buys

Rank Stock Value
1
PM icon
Philip Morris
PM
+$38.3M
2
AMZN icon
Amazon
AMZN
+$27.7M
3
PLTR icon
Palantir
PLTR
+$17.5M
4
HIMS icon
Hims & Hers Health
HIMS
+$13.7M
5
YUMC icon
Yum China
YUMC
+$13.2M

Top Sells

Rank Stock Value
1
PDD icon
Pinduoduo
PDD
+$39.4M
2
NVDA icon
NVIDIA
NVDA
+$30.1M
3
META icon
Meta Platforms (Facebook)
META
+$14.9M
4
BEKE icon
KE Holdings
BEKE
+$14.1M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$11.2M

Sector Composition

Rank Sector Weight
1 Technology 42.45%
2 Consumer Discretionary 16.26%
3 Communication Services 14.17%
4 Healthcare 8.06%
5 Consumer Staples 5.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORKA
576
Oruka Therapeutics
ORKA
$5.9B
$9.19K ﹤0.01%
896
+161
+22% +$2.01K
ALT icon
577
Altimmune
ALT
$580M
$9.11K ﹤0.01%
1,821
+328
+22% +$2.08K
RGNX icon
578
Regenxbio
RGNX
$648M
$9.07K ﹤0.01%
1,269
+229
+22% +$1.7K
BFS
579
Saul Centers
BFS
$850M
$9.02K ﹤0.01%
250
+11
+5% +$403
STOK icon
580
Stoke Therapeutics
STOK
$1.87B
$9.01K ﹤0.01%
1,355
+243
+22% +$2.27K
LKFT
581
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$8.97K ﹤0.01%
357
+64
+22% +$1.62K
TRDA icon
582
Entrada Therapeutics
TRDA
$263M
$8.66K ﹤0.01%
958
+173
+22% +$2.16K
RNAC icon
583
Cartesian Therapeutics
RNAC
$227M
$8.57K ﹤0.01%
650
+116
+22% +$2.07K
OLP
584
One Liberty Properties
OLP
$532M
$8.43K ﹤0.01%
321
+13
+4% +$340
RIGL icon
585
Rigel Pharmaceuticals
RIGL
$704M
$8.11K ﹤0.01%
451
+81
+22% +$1.64K
MRVI icon
586
Maravai LifeSciences
MRVI
$996M
$8.03K ﹤0.01%
3,631
+653
+22% +$2.58K
PACB icon
587
Pacific Biosciences
PACB
$460M
$8.01K ﹤0.01%
6,791
+1,041
+18% +$1.6K
AUTL
588
Autolus Therapeutics
AUTL
$407M
$7.92K ﹤0.01%
5,113
+920
+22% +$1.87K
ALLO icon
589
Allogene Therapeutics
ALLO
$680M
$7.84K ﹤0.01%
5,368
+965
+22% +$1.82K
ATXS
590
DELISTED
Astria Therapeutics
ATXS
$7.71K ﹤0.01%
1,444
+259
+22% +$1.81K
DHC
591
Diversified Healthcare Trust
DHC
$2.17B
$7.58K ﹤0.01%
3,159
+123
+4% +$304
HPP
592
Hudson Pacific Properties
HPP
$766M
$7.5K ﹤0.01%
363
+36
+11% +$753
AURA icon
593
Aura Biosciences
AURA
$735M
$7.5K ﹤0.01%
1,279
+230
+22% +$1.74K
OABI icon
594
OmniAb
OABI
$288M
$7.44K ﹤0.01%
3,099
+558
+22% +$1.83K
ABSI icon
595
Absci
ABSI
$1.29B
$7.38K ﹤0.01%
2,941
+529
+22% +$1.94K
MXCT icon
596
MaxCyte
MXCT
$112M
$7.37K ﹤0.01%
2,701
+486
+22% +$1.92K
ARCT icon
597
Arcturus Therapeutics
ARCT
$168M
$7.34K ﹤0.01%
693
+124
+22% +$1.97K
TSHA icon
598
Taysha Gene Therapies
TSHA
$1.69B
$7.29K ﹤0.01%
5,248
+945
+22% +$1.58K
GLUE icon
599
Monte Rosa Therapeutics
GLUE
$1.92B
$7.29K ﹤0.01%
1,572
+282
+22% +$1.73K
ESPR
600
DELISTED
Esperion Therapeutics
ESPR
$7.26K ﹤0.01%
5,045
+908
+22% +$1.67K
22 23
24
25 26

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GF Fund Management's Q1 2025 Portfolio in Review

As of Q1 2025, GF Fund Management held 683 positions worth $4.26B, down 7.8% from $4.62B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

GF Fund Management's Q1 2025 filing shows 46 new, 475 increased, 93 reduced and 17 closed positions. Its largest new stake was Hims & Hers Health: 368,661 shares worth $10.9M. The largest sale was Pinduoduo, an estimated $39.4M.

By sector, the portfolio is most concentrated in Technology at 42% of assets, down from 45% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • GF Fund Management's largest Q1 2025 buy was Hims & Hers Health: 368,661 shares worth $10.9M.
  • GF Fund Management added most to Philip Morris in Q1 2025, an estimated $38.3M increase.
  • GF Fund Management's biggest Q1 2025 reduction was Pinduoduo, cutting an estimated $39.4M.
  • GF Fund Management fully exited Applied Optoelectronics in Q1 2025, selling an estimated $5.07M.
  • GF Fund Management's ten largest holdings make up 44% of its $4.26B portfolio in Q1 2025.
  • GF Fund Management opened 46 new positions and closed 17 in Q1 2025.
  • GF Fund Management's portfolio value fell 7.8% quarter-over-quarter to $4.26B.

Based on GF Fund Management's 13F filing for Q1 2025, filed 29 Apr 2025.